Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 24;12:1248. doi: 10.1038/s41598-022-05193-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Selumetinib combined with KRT-232 inhibits tumor growth in PTC PDX models. Female athymic nu/nu mice bearing PTC PDXs were treated with vehicle, selumetinib 25 mg/kg, KRT-232 15 mg/kg, or the combination of both. Selumetinib and KRT-232 were both administered daily. Left panel, individual tumor volume change (mm³). Middle panel, growth curve graphs demonstrating mean change in tumor volume percentage ± SEM. Right panel, EFS curves. PDX.008: black arrow, complete regression on day 54, treatments stopped; red arrow, 100% increase in tumor size and treatments restarted on day 68.